Lucira Health, Inc. (LHDX) News
Filter LHDX News Items
LHDX News Results
|Loading, please wait...|
LHDX News Highlights
- For LHDX, its 30 day story count is now at 7.
- Over the past 26 days, the trend for LHDX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- LAW and PTE are the most mentioned tickers in articles about LHDX.
Latest LHDX News From Around the Web
Below are the latest news stories about Lucira Health Inc that investors may wish to consider to help them evaluate LHDX as an investment opportunity.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lucira Health, Inc. - LHDX
Pomerantz LLP is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or the "Company") (NASDAQ: LHDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Lucira Health (LHDX) is an American medical technology company that makes test kits for infectious diseases. Its products include a COVID-19 test kit that can be purchased without a prescription and used at home. (See Analysts’ Top Stocks on TipRanks) Let’s take a look at the company’s latest financial performance, corporate updates, and changes in risk factors. Q2 Financial Results Lucira Health reported revenue of $12.4 million for Q2 2021 and beat consensus estimates of $8 million. The company did not book any revenue in the same quarter last year. It said that the sale of its COVID-19 test kits was a major revenue driver in the latest quarter.
The recall is the latest hiccup in a Covid rapid-testing market already stressed by supply chain issues and test failures.
Singapore Health Sciences Authority issues approval by its Pandemic Special Access Route (PSAR) for the LUCIRA CHECK IT COVID-19 Test Kit. Lucira has partnered with Labgistics Asia Pte Ltd for the importation and distribution of its products in Singapore.EMERYVILLE, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious di
Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Lucira Health, Inc. ("Lucira" or the "Company") (NASDAQ: LHDX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss the
EMERYVILLE, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today commented on the recent recall of the FLOQSwabs by supply partner Copan Italia SPA, or Copan. Copan, who supplies FLOQSwabs included in the LUCIRA COVID-19 All-In-One Test Kit and LUCIRA CHECK IT COVID-19 Test Kit, collectively the T
Veteran operations expert joins Lucira’s management teamEMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced operations expert Tony Allen has joined the company as Chief Operations Officer. “Tony has a stellar track record in operations management. We’re delighted that he’s
EMERYVILLE, Calif., August 23, 2021--Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced life science professional Ghazi Kashmolah has joined the company as Chief Quality Officer and Executive Vice President Regulatory Affairs.
Volatility comes with the territory when you invest in biotech stocks. Here's why they chose Bluebird Bio (NASDAQ: BLUE), Lucira Health (NASDAQ: LHDX), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (Bluebird Bio): Shares of Bluebird Bio have been hammered in recent years.
After the speakers' presentation, there will be a question-and-answer session [Operator instructions] I would now like to hand the conference over to your first speaker today, Hannah Jeffrey from Gilmartin Group. Earlier today, Lucira Health released financial results for the second quarter ended June 30, 2021. Joining me today on today's call are Erik Engelson, president and chief executive officer; and Dan George, chief financial officer.